These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9892384)

  • 61. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients.
    Zehnder C
    Nephron; 1989; 51(3):424-5. PubMed ID: 2918959
    [No Abstract]   [Full Text] [Related]  

  • 62. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
    House AA; Pham B; Pagé DE
    Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis.
    Depner TA; Rizwan S; James LA
    ASAIO Trans; 1990; 36(3):M223-5. PubMed ID: 2252662
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Pharmacokinetics and clinical effect of recombinant human erythropoietin on the anemia of predialysis patients].
    Yamazaki C; Itoh A; Yamamoto N; Kobayashi M; Watanabe Y; Sakamoto N
    Nihon Jinzo Gakkai Shi; 1992 Jun; 34(6):701-10. PubMed ID: 1479710
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Erythropoietin treatment in peritoneal dialysis patients.
    Nissenson AR
    Perit Dial Int; 1994; 14 Suppl 3():S63-9. PubMed ID: 7948280
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 67. Influence of adynamic bone disease on responsiveness to recombinant human erythropoietin in peritoneal dialysis patients.
    Kcomt J; Sotelo C; Raja R
    Adv Perit Dial; 2000; 16():294-6. PubMed ID: 11045314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
    Scigalla P; Messinger D; Wieczorek L
    Contrib Nephrol; 1990; 82():55-64. PubMed ID: 2093527
    [No Abstract]   [Full Text] [Related]  

  • 69. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of anemia in patients on a regular dialysis program using human recombinant erythropoietin].
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartůnková J; Válek A
    Cas Lek Cesk; 1989 Sep; 128(40):1257-60. PubMed ID: 2582471
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Chronic kidney failure, anemia and erythropoietin].
    Sulková S
    Cas Lek Cesk; 1990 May; 129(18):545-9. PubMed ID: 2350772
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of hematocrit in efficiency of dialysis.
    Movilli E; Cancarini GC; Mombelloni S; Feller P; Ravelli M; Maiorca R
    Blood Purif; 1990; 8(4):183-9. PubMed ID: 2085426
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Anemia in the dialyzed patient].
    Deray G
    Soins; 2003 Oct; (679 Suppl):17. PubMed ID: 14621469
    [No Abstract]   [Full Text] [Related]  

  • 78. [Clinical studies of recombinant human erythropoietin in patients on long-term dialysis].
    Ji SM; Li LS; Ji DX
    Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):100-2. PubMed ID: 8404323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
    Richardson D; Lindley EJ; Bartlett C; Will EJ
    Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reasons for producing guidelines on anemia of chronic renal failure: dialysis outcome quality initiative of the National Kidney Foundation.
    Triolo G; Canavese C; Di Giulio S
    Int J Artif Organs; 1998 Nov; 21(11):751-6. PubMed ID: 9894755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.